Brian Lobo
Overview
Explore the profile of Brian Lobo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mulligan J, Nord D, Villanueva M, Justice J, Lobo B, Schlosser R, et al.
J Immunol
. 2022 Jul;
209(2):262-269.
PMID: 35793909
In patients with chronic rhinosinusitis with nasal polyps, primary human sinonasal epithelial cell (HSNEC) 1α-hydroxylase levels are reduced, as is their ability to metabolize 25-hydroxycholecalciferol [25(OH)D] to its active metabolite,...
2.
Manikwar P, Mulagapati S, Kasturirangan S, Moez K, Rainey G, Lobo B
J Pharm Sci
. 2019 Jul;
109(1):220-232.
PMID: 31288034
Bispecific antibodies containing single-chain variable fragment (scFv) appended to immunoglobulins G offer unique development challenges. Here, we describe the stability of a novel bispecific format, BiS5, where the scFv is...
3.
Taraban M, DePaz R, Lobo B, Yu Y
Anal Chem
. 2019 Feb;
91(6):4107-4115.
PMID: 30767509
Water proton transverse relaxation rate R(HO) measurements by NMR stand out as a powerful noninvasive tool to detect protein aggregates, including subvisible particles in biopharmaceutical formulations. To understand the applicability...
4.
Taraban M, DePaz R, Lobo B, Yu Y
Anal Chem
. 2017 Apr;
89(10):5494-5502.
PMID: 28440620
Formulation stability is a critical attribute of any protein-based biopharmaceutical drug due to a protein's inherent tendency to aggregate. Advanced analytical techniques currently used for characterization of protein aggregates are...
5.
Jayaraman J, Wu J, Brunelle M, Cruz A, Goldberg D, Lobo B, et al.
Biotechnol Bioeng
. 2014 Aug;
111(8):1513-20.
PMID: 25097914
One of the most significant challenges in developing therapeutic monoclonal antibodies (mAbs) is their unpredictable solubilities and viscosities at the high concentrations required for subcutaneous delivery. This challenge has motivated...